Receptor editing in self-reactive bone marrow B cells. The Journal of Experimental Medicine. 1993. 177: 1009-1020.

Susan L Tiegs, David M Russell, David Nemazee

Abstract readSeminal Article

In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it

0cells of the map it votes in

3citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

Marginal Zone B-Cell Populations and Their Regulatory Potential in the Context of HIV and Other Chronic Inflammatory Conditions.International journal of molecular sciences · 2022
Review
The role of CD22 and Siglec-G in B-cell tolerance and autoimmune disease.Nature reviews. Rheumatology · 2014
Review
The Role of Natural-Based Biomaterials in Advanced Therapies for Autoimmune Diseases.Advances in experimental medicine and biology
Review

4 · The record

Corrections and comments

Commented on by
Receptor editing as a mechanism of B cell tolerance.2011

5 · Who and what money

Authors and funding

3 authors.

Susan L Tiegs

David M Russell

David Nemazee

Funding

RECEPTOR EDITING IN B-CELLSR01AI033608 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI NEMAZEE, DAVID · 1993 to 2010

$3.7M

B LYMPHOCYTE TOLERANCE IN HEALTH AND AUTOIMMUNITYR01GM044809 · NIGMS · SCRIPPS RESEARCH INSTITUTE, THE · PI NEMAZEE, DAVID · 1990 to 2009

$3.5M

NIAID NIH HHS R01 AI033608NIGMS NIH HHS R01 GM044809

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsAutoantigensB-Lymphocyte SubsetsBone Marrow CellsDNA-Binding ProteinsGene Rearrangement, B-Lymphocyte, Light ChainHomeodomain ProteinsImmunoglobulin lambda-ChainsImmunoglobulin Light ChainsImmunoglobulin MMiceMice, Inbred BALB CMice, KnockoutMice, TransgenicReceptors, Antigen, B-CellAutoantigensDNA-Binding ProteinsHomeodomain ProteinsImmunoglobulin lambda-ChainsImmunoglobulin Light ChainsImmunoglobulin MRAG-1 proteinReceptors, Antigen, B-CellV(D)J recombination activating protein 2

Identifiers

PMID21248269

PMCPMC3792715

What OpenQuestion holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.